Skip to content
SPC Logo

Maxtrex Tablets 2.5 mg

Last Updated on eMC 02-Oct-2014 View document  | Pfizer Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02-Oct-2014 and displayed until Current

Reasons for adding or updating:

  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Jun-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



The only change is the revision date at the end of the SPC.

Updated on 23-Jun-2014 and displayed until 02-Oct-2014

Reasons for adding or updating:

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 01-Apr-2014

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



Change to section 7 -   MAH name changed to Pfizer Limited

Change to section  8 -  product licence number change

Change to section 10  - Date of Revision of text

Updated on 15-Nov-2013 and displayed until 23-Jun-2014

Reasons for adding or updating:

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Date of revision of text on the SPC: 01-Sep-2013

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Update to Section 4.5

Updated on 21-Jun-2012 and displayed until 15-Nov-2013

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.9 - Overdose

Date of revision of text on the SPC: 01-Jun-2012

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:



4.2.   Posology and Method of Administration

4.4.   Special Warnings and Precautions for Use

4.9.   Overdose

Updated on 02-Apr-2012 and displayed until 21-Jun-2012

Reasons for adding or updating:

  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 6. 5 - Nature and Contents of Container

Date of revision of text on the SPC: 01-Mar-2012

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

6.4. Special Precautions for Storage

6.5. Nature and Contents of Container

Updated on 24-Sep-2008 and displayed until 02-Apr-2012

Reasons for adding or updating:

  • Change to section 4.8 - Undesirable Effects

Date of revision of text on the SPC: 01-Aug-2008

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

Section 4.8 of the SPC updated to include anaphylactic reaction as requested by the MHRA

Updated on 10-Aug-2007 and displayed until 24-Sep-2008

Reasons for adding or updating:

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 7 - Marketing Authorisation Holder

Date of revision of text on the SPC: 01-Apr-2007

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

4.5 –sulphinpyrazone to sulfinpyrazone

7 –Milton Keynes address to Sandwich address   

Updated on 01-Nov-2004 and displayed until 10-Aug-2007

Reasons for adding or updating:

  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects

Updated on 05-Jun-2003 and displayed until 01-Nov-2004

Reasons for adding or updating:

  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text

Updated on 24-Sep-2002 and displayed until 05-Jun-2003

Reasons for adding or updating:

  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of Renewal of Authorisation

Updated on 11-Jun-2002 and displayed until 24-Sep-2002

Reasons for adding or updating:

  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 10 (date of (partial) revision of the text

Updated on 24-Jan-2002 and displayed until 11-Jun-2002

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 31-Jul-2001 and displayed until 24-Jan-2002

Reasons for adding or updating:

  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects

Company contact details

Pfizer Limited

Company image
Address

Ramsgate Road, Sandwich, Kent, CT13 9NJ

Fax

+44 (0)1304 656 221

Telephone

+44 (0)1304 616 161

Medical Information Website

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

methotrexate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue